Idinvest Partners, a leading investor in SMEs across Europe, has today announced the final closing of its second capital growth fund (Idinvest Growth Fund II) at €340m, surpassing its initial target of €300m. Idinvest Growth Fund II brings together a panel of renowned investors, of whom more than 75% are based outside France.Since its launch in 2017, the fund has invested 50% of its total commitments across 15 companies, including Ogury, Secret Escapes, Klaxoon, Vestiaire Collective, and Sophia Genetics.
Botify, specialist in organic search marketing, uses its SEO platform to support companies such as Nike, Expedia, Marriott and Conde Nast to build their websites with optimal organic search performance. After an incredible 2018 which saw growth of over 200% for the company in the US, they are opening their 2nd US office in Seattle at the start of March. This, coupled with the new funding led by Idinvest Partners, will enable them to extend their worldwide footprint and will fuel product innovation, customer adoption and success.Benoist [...]
The Berlin-based insurtech firm which facilitates insurance management for companies and their customers has grown its revenues to $40m and now serves more than 1500 brokers and over 400,000 customers. This Series B funding round will help spearhead the company's expansion into the European broker market and enable wefox Group to create an all-in-one insurance platform and connect insurers globally.
Creator of the world's leading employee retention platform, Peakon has closed a $35m extension to their Series B funding round to bring the total to $57m. Their SaaS platform which brings managers and employees together is already used by clients such as Verizon, BMW and easyJet. Following impressive growth in the US market in 2018, the company aims to use this funding round to continue to scale growth in the US and grow their product and engineering teams.
Pfizer has acquired a 15% equity interest in gene therapy company Vivet and secured an exclusive option to acquire the company. The two companies will collaborate with Pfizer on the development of Vivet's proprietary treatment for Wilson disease and this partnership will help them to continue to develop therapies for patients suffering from inherited liver disorders.